Systemic Outcomes of Intravitreal Injections of Dexamethasone and Anti-Vascular Endothelial Growth Factor

Systemic Outcomes of Intravitreal Injections of Dexamethasone and Anti-Vascular Endothelial Growth Factor

Abstract Introduction Intravitreal dexamethasone and anti-vascular endothelial growth factor (anti-VEGF) medications have revolutionized ocular disease management and favorable ocular safety profiles, but few studies have compared their systemic adverse events (SAEs). This study investigated the SAE...

Full description

Bibliographic Details
Main Authors: Tzu-Yi Lin, Yi-Ting Hsieh, Sunir J. Garg, Lee-Jen Chen, Kuan-Jen Chen, Wei-Chi Wu, Chi-Chun Lai, Yih-Shiou Hwang, Eugene Yu-Chuan Kang
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-02-01
Series:Ophthalmology and Therapy
Subjects:
Anti-vascular endothelial growth factor
Dexamethasone
Intravitreal injection
Systemic adverse event
Systemic safety
Online Access:https://doi.org/10.1007/s40123-023-00659-3

Internet

https://doi.org/10.1007/s40123-023-00659-3

Similar Items